SEARCH:   Advanced

Blood, 1 February 2007, Vol. 109, No. 3, pp. 951-953. Prepublished online as a Blood First Edition Paper on October 10, 2006; DOI 10.1182/blood-2006-03-013136. This Article Full Text Full Text (PDF) Supplemental Table and Figures All Versions of this Article: blood-2006-03-013136v1 109/3/951    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Weng, W.-K. Articles by Levy, R. Search for Related Content PubMed PubMed Citation Articles by Weng, W.-K. Articles by Levy, R. Related Collections Neoplasia Immunotherapy Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy Wen-Kai Weng1, Debra Czerwinski1, and Ronald Levy1 1 Division of Medical Oncology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA We have reported that anti-idiotype antibody response and FcRIIIa 158 valine/valine (V/V) genotype both correlate with better outcome in a group of 136 follicular lymphoma patients receiving idiotype vaccination after induction chemotherapy. Here, we examined whether this correlation is related in any way to the chemotherapy response. In patients with complete response (CR), the 5-year progression-free survival (PFS) was 69% for patients with antibody response and/or V/V genotype, while the PFS was only 40% for patients with neither; the median time to progression (TTP) was 10.47 versus 3.46 years (P = .012). In patients with partial response (PR), the 5-year PFS was 57% for patients with antibody response and/or V/V genotype, and 17% for patients with neither; the median TTP was not reached versus 1.31 years (P = .001). This study further confirms the strong association of clinical outcome with antibody response and with the functionally more active form of the Fc receptor in patients receiving idiotype vaccination regardless of their response to induction chemotherapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: W. Z. Ai, R. Tibshirani, B. Taidi, D. Czerwinski, and R. Levy Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma Blood, June 4, 2009; 113(23): 5743 - 5746. [Abstract] [Full Text] [PDF] B. Friedrichs, S. Siegel, M. Kloess, A. Barsoum, J. Coggin Jr., J. Rohrer, I. Jakob, M. Tiemann, K. Heidorn, C. Schulte, et al. Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia J. Immunol., May 1, 2008; 180(9): 6374 - 6384. [Abstract] [Full Text] [PDF] L. Binyamin, R. K. Alpaugh, T. L. Hughes, C. T. Lutz, K. S. Campbell, and L. M. Weiner Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy J. Immunol., May 1, 2008; 180(9): 6392 - 6401. [Abstract] [Full Text] [PDF] E. Carlotti, G. A. Palumbo, E. Oldani, D. Tibullo, S. Salmoiraghi, A. Rossi, J. Golay, A. Pulsoni, R. Foa, and A. Rambaldi Fc{gamma}RIIIA and Fc{gamma}RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab Haematologica, August 1, 2007; 92(8): 1127 - 1130. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020